Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ON 01910

Known as: ON-01910, ON01910 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Purpose: Squamous cell carcinoma (SCC) of the skin is the leading cause of death in patients with the severe generalized form of… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2018
2018
Inhibition of RAS-RAF-ERK-signaling is a major mechanism mediated by the multi-kinase inhibitors sorafenib and regorafenib, the… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2014
2014
ON01910.Na is a highly effective anticancer agent that induces mitotic arrest and apoptosis. Clinical studies with ON01910 in… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
2013
2013
Polo-like kinase 1 (PLK1), one of the key regulators of mitosis, is a target for cancer therapy due to its abnormally high… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2012
2012
ABSTRACTPurposeTo evaluate a mitotic inhibitor, ON01910.Na, as a potential chemotherapeutic agent for brain tumors using a series… Expand
  • figure 1
  • figure 2
  • table I
  • table II
  • table III
2011
2011
ON01910 is a small molecular weight benzyl styryl sulfone currently under investigation as a novel anticancer agent. The purpose… Expand
  • figure 1
  • figure 2
  • table 1
2010
2010
During the preclinical drug discovery process it remains a challenge to enable early elimination of candidate molecules that may… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 4
Review
2009
Review
2009
Purpose:Antimitotic chemotherapy remains a cornerstone of multimodality treatment for locally advanced andmetastatic cancers.To… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Highly Cited
2005
Highly Cited
2005
Elevated expression of polo-like kinase1 (Plk1) has been reported in many human tumors, and inhibition of Plk1 activity results… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4